Asahi Kasei Corporation (TYO:3407)
Japan · Delayed Price · Currency is JPY | Market Cap | 2.17T +30.8% |
| Revenue (ttm) | 3.16T +4.0% |
| Net Income | 192.84B +59.9% |
| EPS | 142.18 +61.6% |
| Shares Out | 1.35B |
| PE Ratio | 11.35 |
| Forward PE | 13.21 |
| Dividend | 44.00 (2.73%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 7,350,600 |
| Open | 1,617.50 |
| Previous Close | 1,613.50 |
| Day's Range | 1,599.50 - 1,623.50 |
| 52-Week Range | 1,157.00 - 1,906.00 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 1,981.67 (+22.86%) |
| Earnings Date | Nov 5, 2026 |
About Asahi Kasei
Asahi Kasei Corporation engages in material, homes, and healthcare businesses in Japan, the United States, China, and internationally. The company offers Pimel, a photosensitive PI material applied for semiconductor applications, such as buffer coating, passivation layers, and dielectric layers; Sunfort, a dry film photoresist; Novacure, a latent curing agent for epoxy resin; glass fabric for printed circuit boards; plastic optical fiber; sensors and devices; artificial suede products under the Dinamica name; Microza UF and MF industrial membra... [Read more]
Financial Performance
In fiscal year 2026, Asahi Kasei's revenue was 3.07 trillion, an increase of 1.22% compared to the previous year's 3.04 trillion. Earnings were 158.79 billion, an increase of 17.63%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for 3407 stock is "Buy." The 12-month stock price target is ¥1,982, which is an increase of 22.86% from the latest price.
News
Asahi Kasei Wins FDA Approval For HOVILPRI To Treat Drug-Resistant HSV In Immunocompromised Adults
(RTTNews) - Asahi Kasei Therapeutics, the specialty pharmaceutical arm of Japan's Asahi Kasei Corporation (AHKSF, 3407.T), secured U.S. Food and Drug Administration approval for HOVILPRI (pritelivir) ...
Asahi Kasei Therapeutics Announces FDA Approval of HOVILPRI® (pritelivir) Tablets for Mucocutaneous HSV Lesions Refractory (With or Without Resistance) to Standard Antiviral Treatment in Immunocompromised Adults
TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, t...
US FDA approves Asahi Kasei's drug for persistent herpes infections
The US FDA on Friday approved Japan's Asahi Kasei's drug for persistent herpes simplex virus sores in certain patients with weakened immune systems who have not responded to available antiviral trea...
Asahi Kasei Microdevices Holds IEEE Milestone Commemoration Ceremony in Nobeoka for the Commercialization of Thin-Film Hall Elements
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices held a ceremony to celebrate the recognition of the 1983 commercialization of thin-film Hall elements as an IEEE Milestone.
Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients
TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics announced that the first patient has been dosed in a randomized Phase 2a clinical trial (NCT07503561) evaluating AIC468.
Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics
TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Veloxis Pharmaceuticals, Calliditas Therapeutics, and AiCuris will come together under the Asahi Kasei Therapeutics brand.
Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing
GLENVIEW, Ill.--(BUSINESS WIRE)--Asahi Kasei Bioprocess will unveil the VANTIJ® SU-VFC Benchtop at Bioprocess International East (BPI EAST) 2026.
Asahi Kasei Microdevices' CZ39 and CZ3K Current Sensors Featured in Microchip Technology's Machine Learning-Based Arc Fault Detection Reference Design
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices has announced that its CZ39 and CZ3K series have been adopted as in Microchip Technology's ML/AI-based AFD reference design.
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy
TOKYO--(BUSINESS WIRE)--Asahi Kasei held a grand opening ceremony for its new Hipore™ wet-process lithium-ion battery separator coating line in Charlotte, North Carolina.
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
TOKYO--(BUSINESS WIRE)--Asahi Kasei has developed a novel pre-doping technology for high-voltage lithium-ion batteries (LIBs) with silicon-based anodes.
Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
TOKYO--(BUSINESS WIRE)--Asahi Kasei's project to build new facilities for electrolysis equipment has been awarded key regional economic incentives.
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China
TOKYO--(BUSINESS WIRE)--HighChem Shanghai to produce Acetolyte™ for sale to battery manufacturers in China.
Asahi Kasei Quarterly report: Q1 2027
Asahi Kasei has published its Q1 2027 quarterly earnings report on July 30, 2026.
Asahi Kasei Slides: Q1 2027
Asahi Kasei has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 30, 2026.
Asahi Kasei Microdevices Begins Mass Production of Camera‑less Modules for Detection of Falls, Vital Signs, Posture, and Position
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices began mass production of the AK5816AIM, an AiM mmWave radar module.
Asahi Kasei's Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time
TOKYO--(BUSINESS WIRE)--Peptistar has integrated Asahi Kasei's novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of APIs.
EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei's Novel Electrolyte Acetolyte™
DUSSELDORF, Germany--(BUSINESS WIRE)--EAS Batteries has commercialized its ultra-high-power lithium-ion LFP cell which incorporates Asahi Kasei's novel Acetolyte™.
Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute – A Major Milestone for More Efficient and Safer Cancer Treatments
TOKYO--(BUSINESS WIRE)--Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging
TOKYO--(BUSINESS WIRE)--Asahi Kasei has combined the features of its photosensitive polyimide (PSPI) and dry film photoresist (DFR) into a new photosensitive film.
Asahi Kasei Microdevices Debuts AK491x Premium Audio Op Amps at HIGH END Vienna 2026
TOKYO--(BUSINESS WIRE)--Asahi Kasei Microdevices (AKM) has unveiled the AK491x series of premium audio operational amplifiers (op amps).
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, has announced plans to streamline operations at its Mizushima Works by fiscal 2030.
Asahi Kasei Slides: Q4 2026
Asahi Kasei has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 11, 2026.
Asahi Kasei Quarterly report: Q4 2026
Asahi Kasei has published its Q4 2026 quarterly earnings report on May 11, 2026.
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
TOKYO--(BUSINESS WIRE)--Asahi Kasei has announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris).
Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases
TOKYO--(BUSINESS WIRE)--Asahi Kasei announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound.